JMP Securities Initiates Coverage On MBX Biosciences with Market Outperform Rating, Announces Price Target of $38

Benzinga · 04/10 13:42
JMP Securities analyst Jonathan Wolleben initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Market Outperform rating and announces Price Target of $38.